Omico

Omico Facilitating, supporting, and promoting clinical trials in genomic cancer medicine.

Professor David Thomas shared powerful evidence at the launch of Omico’s Impact Report.“Over almost a decade, more than ...
30/12/2025

Professor David Thomas shared powerful evidence at the launch of Omico’s Impact Report.
“Over almost a decade, more than two-thirds of the Australians we serve have had actionable biomarkers identified.”

The progress is clear:
60% in 2016 → 69% on average across the decade → 85% today.

As David said: “That’s 5 in 6 people who stand to benefit from molecular profiling today.”

This is why mainstreaming precision oncology matters.

Australians can’t wait.

📘 Omico’s Impact Report – From Momentum to Mainstream: https://bit.ly/44JG6jY
📊 Omico’s Impact Scorecard: https://bit.ly/4rJKd9u

28/12/2025

“Regardless of what cancer stage you are at, speak to your oncologist about comprehensive genomic testing.”

Comprehensive Genomic Profiling (CGP) gave Marina and her oncologist the crucial information needed to understand her challenging cancer and how to treat it.

It’s a conversation worth having early — particularly for people with advanced, incurable or poor-prognosis cancers. Your oncologist can help you understand how and when CGP might help guide your treatment options.

📽️Watch Marina’s story: https://vimeo.com/1130724354
📘Download our Patient Information Booklet and speak to your oncologist: https://qrco.de/bgARbU

At the launch of Omico’s Impact Report, Emily Lahey shared a message that resonated with everyone — including the Hon. M...
23/12/2025

At the launch of Omico’s Impact Report, Emily Lahey shared a message that resonated with everyone — including the Hon. Minister Mark Butler, MP.

💬“I stand here today because I had the opportunity to benefit from genomic testing and targeted therapy… My hope is that my story becomes the rule and not the exception.”

Emily’s story shows why mainstreaming precision oncology is so important.

Australians can’t wait.

📘 Omico’s Impact Report – From Momentum to Mainstream: https://bit.ly/44JG6jY
📊 Omico’s Impact Scorecard: https://bit.ly/4rJKd9u

As we head into the holiday season, we wish all our program participants, partners and stakeholders a peaceful and resto...
22/12/2025

As we head into the holiday season, we wish all our program participants, partners and stakeholders a peaceful and restorative break.

Our Cancer Screening Program (CaSP) team will continue to respond to enquiries during this period, with a reduced team operating from 23 December to 4 January.

📩Please contact us at casp@omico.org.au and we’ll respond as soon as we can.

At the launch of Omico’s Impact Report, our new Chair, Richard Vines, acknowledged what has been built:💬“About 10 years ...
22/12/2025

At the launch of Omico’s Impact Report, our new Chair, Richard Vines, acknowledged what has been built:
💬“About 10 years ago I was talking to David about his vision for Omico… I said to him that if you can do this, then what you would have created is a national treasure for this country. And he has.”

A powerful reminder of how far this vision has come to accelerate equitable access to precision oncology, and what’s now possible for Australians facing cancer.

Read more about this progress:
📘 Omico’s Impact Report – From Momentum to Mainstream: https://bit.ly/44JG6jY
📊 Omico’s Impact Scorecard: https://bit.ly/4rJKd9u

Australians can’t wait. It’s time to mainstream precision oncology for those who need it most.

After our Impact Report launch, Dr Mike Freelander MP gave a speech in Parliament recognising Omico’s work.He spoke warm...
18/12/2025

After our Impact Report launch, Dr Mike Freelander MP gave a speech in Parliament recognising Omico’s work.

He spoke warmly about our founder:
“Professor David Thomas is a rockstar in the medical world.”

He also underscored how precision oncology is already transforming care:
💬“Omico is really changing lives of many people.”
💬“We have cutting-edge genomic technologies that are turning into tangible therapeutic advancements for Australians with challenging cancers, improving outcomes across the board.”

We’re grateful to Dr Freelander for highlighting Omico’s impact — and the potential ahead.

🎥 Watch his speech: https://vimeo.com/1142726020

Read more about our impact:
📘 Omico’s Impact Report – From Momentum to Mainstream: https://bit.ly/44JG6jY
📊 Omico’s Impact Scorecard: https://bit.ly/4rJKd9u

Australians can’t wait. It’s time to mainstream precision oncology for those who need it most.

When Jason came to Caroline (his oncologist) and asked how they were going to fight his cancer, she didn't hesitate in r...
18/12/2025

When Jason came to Caroline (his oncologist) and asked how they were going to fight his cancer, she didn't hesitate in recommending comprehensive genomic profiling (CGP).

"We need to do CGP to understand your cancer...(and) what can we offer you that's matched to your type of cancer."

Current data from our Cancer Screening Program (CaSP), show that CGP identifies a biomarker with a matched therapy or clinical trial in around 85% of participants — opening the door to personalised options, as it did for Jason.

📽️Watch Jason’s full story: https://vimeo.com/1130722696
📘Download our Patient Information Booklet and speak to your oncologist: https://qrco.de/bgARbU

At Parliament House, Professor David Thomas recently shared why the need for better access to precision oncology is so u...
17/12/2025

At Parliament House, Professor David Thomas recently shared why the need for better access to precision oncology is so urgent — and what the numbers are telling us.

💬“Every 15 minutes, Omico receives another referral for a patient with an incurable cancer diagnosis…
We're providing support to ~1 in 5 cancer patients who are not going to be cured of their disease.”

Access to precision oncology - molecular profiling and matching to precision therapies - can open the door to new treatment options, may help extend life and give more moments with loved ones.

This is why mainstreaming precision oncology is so important — many more Australians could benefit.

Australians can’t wait.

📘 Omico’s Impact Report – From Momentum to Mainstream: https://bit.ly/44JG6jY
📊 Omico’s Impact Scorecard: https://bit.ly/4rJKd9u

12/12/2025

Speaking to your oncologist – a partnership to outsmart cancer.

For Jason and his medical oncologist, Dr Caroline Lum, Comprehensive Genomic Profiling (CGP) provided the essential information they needed – identifying the biomarkers driving his cancer and
helping to uncover matched treatment options based on those specific features.

“Absolute shining star…outsmarting what is a very smart beast with you” – Jason speaking about his medical oncologist.

📽️Watch Jason’s full story: https://vimeo.com/1130722696
📘Download our Patient Information Booklet and speak to your oncologist: https://qrco.de/bgARbU

At the launch of Omico’s Impact Report, Health Minister Mark Butler called Australia’s progress in precision oncology:💬“...
11/12/2025

At the launch of Omico’s Impact Report, Health Minister Mark Butler called Australia’s progress in precision oncology:

💬“The numbers are, frankly, jaw-dropping… extended life, survival rates, and matching patients to targeted therapies.”

Omico CEO Ian Black welcomed the Government’s support and highlighted the urgency:
💬“Time is of the essence — we can’t afford to lose momentum… we must act now so no one is left behind.”

Learn more:
📘 Omico’s Impact Report – From Momentum to Mainstream: https://bit.ly/44JG6jY
📊 Omico’s Impact Scorecard: https://bit.ly/4rJKd9u

Australians can’t wait. It’s time to mainstream precision oncology for those who need it most.

Six years ago, Emily Lahey was given 6–9 months to live.She’s 33 now — and she’s still here.At the launch of Omico’s Imp...
08/12/2025

Six years ago, Emily Lahey was given 6–9 months to live.
She’s 33 now — and she’s still here.

At the launch of Omico’s Impact Report: From Momentum to Mainstream at Parliament House last week, Emily shared why — and what precision oncology has meant for her life. As she said:
💬“My story illustrates the real-world impact of precision medicine.”

You can read Emily’s story, and learn more about what’s now possible for Australians facing incurable cancer here:
📘 Omico’s Impact Report – From Momentum to Mainstream: https://bit.ly/44JG6jY
📊 Omico’s Impact Scorecard: https://bit.ly/4rJKd9u

Australians can’t wait. It’s time to mainstream precision oncology for those who need it most.



Rare Cancers Australia

04/12/2025

Congratulations to Cancer Institute NSW on releasing Cancer in NSW 2025 this week.

The report provides a clear picture of cancer in our state — the progress made, the challenges ahead, and the collective effort needed to build a future beyond cancer.

Omico is proud to contribute to this snapshot of cancer control in NSW. With support from NSW Government, we’ve accelerated access to precision oncology for people with incurable cancer in NSW — providing free comprehensive genomic profiling and matching to personalised treatment options or clinical trials based on the unique features of each tumour. This work also forms part of Omico’s broader national programs, which reach Australians no matter where they live.

Our vision is for precision oncology to become routine, funded care for every Australian who can benefit.

An important read – and if you’re looking for our contribution, you’ll find it on page 62.

Link to Cancer in NSW 2025: www.cancer.nsw.gov.au/cancer-in-nsw-2025



UNSW University of Sydney UNSW Medicine & Health Cancer Council Australia Rare Cancers Australia

Address

370 Victoria St, Darlinghurst
Sydney, NSW
2010

Website

Alerts

Be the first to know and let us send you an email when Omico posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Omico:

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category